Researchers found that a single dose of a new gene-editing treatment, EDIT-401, significantly reduced levels of harmful lipoproteins in non-human primates. Specifically, it achieved over a 90% reduction in low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB). These lipoproteins are key contributors to cardiovascular disease, making this discovery potentially transformative for people at risk of heart problems.

This matters for your health because high levels of LDL-C, Lp(a), and ApoB are associated with increased cardiovascular risk. If successful in humans, EDIT-401 could offer a powerful new option for individuals with high cholesterol levels, particularly those with conditions like heterozygous familial hypercholesterolemia (HeFH). The treatment could lead to substantial improvements in heart health, helping to lower the risk of heart attacks and strokes.

The evidence is based on early-stage preclinical studies in non-human primates, which show promising results but are not yet proven in humans. Editas Medicine plans to submit a Clinical Trial Notification (CTN) by mid-2026 to begin human trials and aims to have early data on its effectiveness by the end of that year. While these results are encouraging, it’s important to remember that they are preliminary, and further research is needed to confirm the treatment’s safety and efficacy in people.

For now, if you’re concerned about cholesterol and heart health, consider discussing lifestyle changes with your healthcare provider, such as diet and exercise, which can also help manage cholesterol levels effectively.

Source: globenewswire.com